Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03384745 · ClinicalTrials.gov registry record · Phase 2
A Phase 2b Study of the Efficacy, Safety, and Tolerability of M1095 (Sonelokimab) in Subjects With Moderate to Severe Psoriasis
A Phase 2 study, sponsored by Bond Avillion 2 Development.
- Completed
- Registry status
- Phase 2
- Development phase
- 313
- Enrollment target
NCT03384745: Completed Phase 2 study, sponsored by Bond Avillion 2 Development.
NCT03384745 is a Phase 2 study that has completed, run by Bond Avillion 2 Development. The registered enrollment target is 313 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03384745, a Phase 2 study, has completed, sponsored by Bond Avillion 2 Development.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 313 participants
- Enrollment target
Study Summary
This is a multi-center phase 2b study in subjects with moderate to severe chronic plaque-type psoriasis. Approximately 300 subjects will be enrolled at approximately 60 investigator sites in North America and Europe.
Interventions
- DRUG Placebo
- DRUG Secukinumab
- DRUG M1095 (Sonelokimab)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 313 participants |
| Start Date | 2018-07-31 |
| Est. Completion | 2020-03-26 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03384745
The ClinicalTrials.gov registry entry for NCT03384745 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 313 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bond Avillion 2 Development, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT03384745 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03384745 about?
NCT03384745 is a clinical study titled "A Phase 2b Study of the Efficacy, Safety, and Tolerability of M1095 (Sonelokimab) in Subjects With Moderate to Severe Psoriasis". This is a multi-center phase 2b study in subjects with moderate to severe chronic plaque-type psoriasis. Approximately 300 subjects will be enrolled at approximately 60 investigator sites in North America and Europe.
What is the current status of trial NCT03384745?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 313 participants. The study started on 2018-07-31. Estimated completion is 2020-03-26.
What interventions are being tested in trial NCT03384745?
The interventions under investigation include: Placebo (DRUG), Secukinumab (DRUG), M1095 (Sonelokimab) (DRUG).
Who is sponsoring clinical trial NCT03384745?
This trial is sponsored by Bond Avillion 2 Development, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.